President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
50-Year Medalist StudyClinical Research
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control

Activity Description

Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control

Birmingham, Alabama
Saturday, July 20, 2013
8:30 am - 1:00 pm
Statement of Need

People with diabetes often have comorbidities or concurrent clinical issues that affect the design and implementation of a glycemic control program. Primary care clinicians oversee the management of most patients who have diabetes, and are often the ones who must balance the need for glycemic control with adaptations of care necessitated by the presence of confounding comorbid conditions. For that reason, the Joslin Diabetes Forum 2013 will focus on the clinical overlap that occurs when glucose control programs are designed for people who have confounding clinical issues. Sessions will address the need for treatment adaptation for confounding clinical issues such as older age, obesity, reduced renal function, cardiovascular disease, or elevated liver function tests. The goal of this year's Forum is to help clinicians learn how to adapt basic glycemic control programs to safely achieve glycemic goals for their patients.

Target Audience

This certified live activity has been developed for primary care providers and their clinical and office staff. There is no fee to attend this live activity. However, space is limited, and reservations will be accepted on a first-come, first-served basis. Only clinicians can be admitted. Guests who are not clinicians cannot be accommodated.


7:30 am Registration and Breakfast
8:30 Welcome, Opening Remarks, Pretest, and Brief Discussion of Goals, Objectives, and Barriers to Optimal Care and Outcomes
8:45 Medications to Treat Type 2 Diabetes: Matching the Options to Needs
9:20 Insulin Replacement Therapy: Individualizing the Design and Management
9:55 Question and Answer Session: Glucose Control Basics
10:05 Glucose Management in the Context of Confounding Conditions: Making the Therapy Fit the Patient (Five Case Scenarios)
10:05 Elderly
10:20 Reduced Renal Function
10:35 Break
10:50 Obesity
11:05 Elevated Liver Enzymes/Fatty Liver
11:20 Coronary Artery Disease
11:35 Case Workshop: Two Cases
12:40 pm Question and Answer Session: Scenarios and Workshop
1:00 Concluding Remarks and Adjournment

Learning Objectives

Participants will be provided with clinically relevant, evidence-based information. Upon completion of this activity, participants should be able to:

  • Describe the role that each of the key classes of antidiabetes medications have in targeting the specific etiologic causes of hyperglycemia
  • Discuss the systematic approach to glycemic pattern assessment and how it can be used to initiate and titrate insulin therapy
  • Demonstrate how key confounding conditions that commonly accompany diabetes (aging, renal dysfunction, coronary artery disease, elevated liver enzymes/fatty liver, & obesity) impact design and management of a glycemic control program
  • Demonstrate the ability to adjust glycemic treatments to optimize control and also compensate for common confounding comorbidities

This activity has been designed to address and encourage the following IOM/ACGME Competencies:

  • Medical knowledge
  • Professionalism
  • Evidence-based practice

Speakers for this activity will be drawn from the distinguished faculty listed below.*

Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director, Professional Education
Joslin Diabetes Center
Boston, MA

Susan Herzlinger Botein, MD
Harvard Medical School
Joslin Diabetes Center
Boston, MA

Aaron M. Cypess, MD, PhD, MMSc
Assistant Professor
Harvard Medical School
Assistant Investigator and Staff Physician
Joslin Diabetes Center
Boston, MA

Osama Hamdy, MD, PhD, FACE
Harvard Medical School
Medical Director, Obesity Clinical Program
Joslin Diabetes Center
Boston, MA

Ruth Hertzman-Miller, MD, MPH
Director of Medical Programs
Professional Education
Joslin Diabetes Center
Boston, MA

Lyle D. Mitzner, MD
Instructor in Medicine
Harvard Medical School
Attending Physician in Endocrinology
Beth Israel Deaconess Medical Center
Staff Physician
Joslin Diabetes Center
Boston, MA

Mark E. Molitch, MD
Professor of Medicine
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Medha Munshi, MD
Assistant Professor of Medicine
Harvard Medical School
Director of Joslin Geriatric Diabetes Programs
Beth Israel Deaconess Medical Center
Boston, MA

*Faculty list subject to change

Accreditation and Designation of Credit

Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME live activity was planned and produced in accordance with ACCME Essentials. Health professionals not eligible for continuing medical education credit will receive a certificate of participation that they may submit to their state licensing board for credit.

Disclosure Policy

It is the policy of Joslin Diabetes Center to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by Joslin Diabetes Center are required to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, Novo Nordisk Inc., Sanofi USA LLC, and Daiichi Sankyo, Inc.

Page last updated: June 22, 2018